

FIG. 1




FIG. 2

3 / 36





FIG. 3

20120429 12:23:00

4 / 36

FIG. 4



5 / 36




FIG. 5

6 / 36




FIG. 6

2014-04-24 14:22:00

7 / 36






FIG. 7

8 / 36

FIG. 8



9/36



10 / 36




FIG. 10

2014220 123000

11 / 36




FIG. 11

12 / 36





FIG.12


13 / 36

FIG. 13




2013/02/20 14:29:00

14 / 36



15 / 36


FIG. 15



2007-07-27 14:23:03

16 / 36

FIG. 16



17 / 36

FIG. 17A




FIG. 17B






FIG. 17C



Legend:


- DISEASE FREE (hatched)
- UNTREATED CONTROL (white)
- PS/2 TREATED (diagonal lines)
- RAT IgG2b TREATED CONTROL (cross-hatched)

FIG. 18




19 / 36

1 (200 MICROGRAM) PS/2 TREATMENT / 1DAY N=3 / GROUP



2 (200 MICROGRAM) PS/2 TREATMENTS / 2DAYS N=3 / GROUP



6 (200 MICROGRAM) PS/2 TREATMENTS / 6DAYS N=5 / GROUP






FIG. 19


20 / 36



20 / 36


21 / 36

FIG. 21



22 / 36

FIG. 22



23 / 36






FIG. 24



25 / 36



26 / 36

FIG. 26A




FIG. 26B





FIG. 26C



27 / 36

FIG. 27A





FIG. 27B




28 / 36

FIG. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECTED	NONE DETECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

29 / 36

FIG. 29



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP

- DISEASE FREE CONTROL
- UNTREATED MYELOMA CONTROL
- PS/2--100 MICROGRAMS/INJECTION
- Sm.Mol. 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg
- Sm.Mol. 9257 CONTROL--3 mg/kg

30 / 36

FIG. 30A




FIG. 30B




FIG. 30C




FIG. 31A

31 / 36




FIG. 31B




FIG. 31C





FIG. 32



GROUPS N=2/GROUP
DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
PS/2--100 MICROGRAMS/INJECTION
8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg
9257 CONTROL--3 mg/kg

FIG. 33A

33 / 36




FIG. 33B





FIG. 33C



34 / 36

FIG. 34A






FIG. 34B



35 / 36

FIG. 35



36 / 36

FIG. 36

